Olig1 Antibody Summary
| Immunogen |
Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human OLIG1. The exact sequence is proprietary.
|
| Localization |
Nucleus
|
| Predicted Species |
Bovine (100%). Backed by our 100% Guarantee.
|
| Isotype |
IgG
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
OLIG1
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
| Theoretical MW |
28 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
Packaging, Storage & Formulations
| Storage |
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
|
| Buffer |
PBS (pH 7.0) and 10% Glycerol
|
| Preservative |
0.01% Thimerosal
|
| Concentration |
1 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for Olig1 Antibody
- BHLHB6
- bHLHe21
- Class B basic helix-loop-helix protein 6
- Class E basic helix-loop-helix protein 21
- helix-loop-helix protein, class B, 6
- Olig1
- oligo1
- oligodendrocyte lineage transcription factor 1
- oligodendrocyte transcription factor 1
- oligodendrocyte-specific bHLH transcription factor 1
Background
Olig genes have been identified as the earliest known markers of oligodendrocyte lineage determination to date (Zhou et al., 2000). Olig1 is a transcription factor which promotes formation and maturation of oligodendrocytes, especially within the brain. It is expressed in the ventral spinal cord as early as 9.5 dpc and by 15.5 dpc, olig1 is dispersed throughout the gray matter. In the postnatal brain, it is present preferentially in the white matter, such as corpus callosum and cerebellar medulla. Olig1 has been demonstrated as necessary in the repair of brain lesions in patients with multiple sclerosis (Arnett et al. 2004).